help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bereket, A.
Right arrow Articles by Wilson, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bereket, A.
Right arrow Articles by Wilson, T. A.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 3647-3652, Copyright © 1995 by Endocrine Society


ARTICLES

Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young

A Bereket, CH Lang, SL Blethen and TA Wilson
Department of Pediatrics, State University of New York, Stony Brook 11794, USA.

The regulation of circulating insulin-like growth factor-binding protein-2 (IGFBP-2) in humans is not well understood. In vitro and animal data have identified the role of insulin in the regulation of IGFBP-2, but such a relationship has not been established clearly in humans. In the present study, serum IGFBP-2 concentrations were assessed by Western ligand blot and immunoblot analysis in children with newly diagnosed and untreated insulin-dependent diabetes mellitus (IDDM) and maturity-onset diabetes of the young before and at various times after insulin therapy. For comparison, IGFBP-2 levels were also determined in lean and obese age-matched controls. Children with IDDM were grouped according to their serum bicarbonate levels at the time of presentation (group A, > 20; group B, 13-20; group C, < 13 milliequivalents/L). Densitometric analysis demonstrated that before insulin therapy, group A patients had serum IGFBP-2 levels comparable to those in lean controls, and no significant change in IGFBP-2 was observed during insulin therapy. However, group B patients had a 2-fold elevation in IGFBP-2 levels before insulin therapy compared to lean controls. In these patients, IGFBP-2 tended to decrease at 1 week, but was not significantly reduced until 1 month after the initiation of insulin therapy. Group C patients had a 2.5-fold elevation of IGFBP-2 before treatment, which normalized by 1 month after treatment. Children with maturity-onset diabetes of the young, who had insulin levels and body mass indexes greater than IDDM patients and lean controls, had significantly lower IGFBP-2 levels than both lean and obese controls. IGFBP-2 levels tended to decrease further during insulin therapy. These results indicate that long standing alterations in serum insulin concentrations beyond the physiological range have significant influence on serum IGFBP-2 levels in children and confirm earlier findings that serum IGFBP-2 levels are not acutely regulated by insulin.


This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
G. Fanciulli, A. Delitala, and G. Delitala
Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone
Hum. Reprod. Update, May 1, 2009; 15(3): 341 - 358.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. L. Ahmed, W. Thomas, and K. H. Schmitz
Interactions between Insulin, Body Fat, and Insulin-Like Growth Factor Axis Proteins
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 593 - 597.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. C. Crowne, J. S. Samra, T. Cheetham, C. L. Acerini, A. Watts, J. M. P. Holly, and D. B. Dunger
The Role of IGF-Binding Proteins in Mediating the Effects of Recombinant Human IGF-I on Insulin Requirements in Type 1 Diabetes Mellitus
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3686 - 3691.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. A. BROCKMANN, C. S. HALEY, E. WOLF, S. KARLE, J. KRATZSCH, U. RENNE, M. SCHWERIN, and A. HOEFLICH
Genome-wide search for loci controlling serum IGF binding protein levels of mice
FASEB J, April 1, 2001; 15(6): 978 - 987.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. I. Helle, T. Ueland, D. Ekse, S. S. Frøland, J. M. P. Holly, P. E. Lønning, and P. Aukrust
The Insulin-Like Growth Factor System in Human Immunodeficiency Virus Infection: Relations to Immunological Parameters, Disease Progression, and Antiretroviral Therapy
J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 227 - 233.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
A. Hoeflich, M. Wu, S. Mohan, J. Föll, R. Wanke, T. Froehlich, G. J. Arnold, H. Lahm, H. J. Kolb, and E. Wolf
Overexpression of Insulin-Like Growth Factor-Binding Protein-2 in Transgenic Mice Reduces Postnatal Body Weight Gain
Endocrinology, December 1, 1999; 140(12): 5488 - 5496.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society